Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Short-term Investments (2023 - 2025)

Mangoceuticals' Short-term Investments history spans 3 years, with the latest figure at $33899.0 for Q4 2025.

  • On a quarterly basis, Short-term Investments rose 100.09% to $33899.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $33899.0, a 100.09% increase, with the full-year FY2025 number at $33899.0, up 100.09% from a year prior.
  • Short-term Investments hit $33899.0 in Q4 2025 for Mangoceuticals, up from $16942.0 in the prior quarter.
  • Over the last five years, Short-term Investments for MGRX hit a ceiling of $33899.0 in Q4 2025 and a floor of $16942.0 in Q4 2023.
  • Historically, Short-term Investments has averaged $19364.4 across 3 years, with a median of $16942.0 in 2023.
  • Biggest five-year swings in Short-term Investments: changed 0.0% in 2024 and later skyrocketed 100.09% in 2025.
  • Tracing MGRX's Short-term Investments over 3 years: stood at $16942.0 in 2023, then changed by 0.0% to $16942.0 in 2024, then skyrocketed by 100.09% to $33899.0 in 2025.
  • Business Quant data shows Short-term Investments for MGRX at $33899.0 in Q4 2025, $16942.0 in Q3 2025, and $16942.0 in Q2 2025.